Compounded tirzepatide vs Zepbound. What actually matters.

Quick comparison at a glance

The short version — here is how Compounded Tirzepatide and Zepbound stack up on the questions most patients ask before picking one.

Compounded Tirzepatide

• Drug class: Dual GLP-1/GIP receptor agonist, compounded
• Brand names: (custom compounded formulations)
• Mechanism: Same active ingredient as brand tirzepatide — a dual GLP-1 and GIP receptor agonist that mimics both gut hormones.
• Dosing: Typically once-weekly subcutaneous injection. Dose ranges and titration schedules depend on the pharmacy and prescriber.
• Half-life: Tirzepatide's half-life is about 5 days regardless of source.
• FDA indication: None — compounded tirzepatide is not an FDA-approved product and does not carry an indication. Prescribed off-label at the physician's discretion for weight management.
• FDA status: NOT FDA-approved. Compounded by state-licensed pharmacies under valid prescriptions, subject to federal and state compounding rules during declared shortages.
• Manufacturer: Licensed compounding pharmacies (not Eli Lilly, not any brand manufacturer).
• Common side effects: Expected similar profile to brand tirzepatide — nausea, vomiting, diarrhea, decreased appetite — but compounded-product-specific safety has not been independently evaluated by the FDA.
• Typical price range: Typically $200-$500/month depending on the pharmacy and dose. Puri's compounded tirzepatide program starts at $249/month when clinically appropriate.

Zepbound

• Drug class: Dual GLP-1/GIP receptor agonist, FDA-approved finished drug product
• Brand names: Zepbound (tirzepatide)
• Mechanism: Synthetic tirzepatide that acts on both GLP-1 and GIP receptors. FDA-approved for chronic weight management.
• Dosing: Once-weekly subcutaneous injection. Titrated from 2.5 mg to a maximum of 15 mg over 20-24 weeks per the FDA-approved prescribing information.
• Half-life: Approximately 5 days.
• FDA indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
• FDA status: FDA-approved in 2023 following the SURMOUNT-1 Phase 3 trial. Continues to be monitored under FDA post-market surveillance.
• Manufacturer: Eli Lilly
• Common side effects: Nausea, vomiting, diarrhea, constipation, decreased appetite. Characterized from SURMOUNT-1 and ongoing post-market surveillance in FDA-approved settings.
• Typical price range: Roughly $1,100-1,400/month cash price without insurance. Some insurance plans cover it for the FDA-approved indication with prior authorization; many do not.

Why tirzepatide compounding is more complicated than semaglutide

Tirzepatide is a newer drug than semaglutide, and its compounding story has been more contested. Eli Lilly has publicly opposed compounding of tirzepatide, arguing that the molecule is complex and difficult to compound safely. The FDA has issued specific guidance on tirzepatide compounding that has evolved over time.

Key points to understand:

• API sourcing is critical. Tirzepatide API should be sourced from FDA-registered manufacturing facilities with documented chain of custody. The FDA has warned about counterfeit or unapproved tirzepatide API circulating in the US market.
• "Salt form" warnings. The FDA has specifically flagged compounded products labeled as "tirzepatide salt" or other alternative chemical forms. These are not the same as the pharmacologically active tirzepatide and may be unsafe or ineffective. Any compounded tirzepatide product should be the base molecule from a legitimate source — not a salt form or alternative.
• Shortage status changes. The legal basis for compounding tirzepatide depends on the drug's FDA shortage status, which has changed multiple times. When Zepbound is off the shortage list, routine compounding of the molecule becomes more restricted.

What Zepbound's FDA approval actually bought

Zepbound's FDA approval in 2023 was based on the SURMOUNT-1 trial, which enrolled 2,539 adults with obesity or overweight and a weight-related condition, and followed them for 72 weeks. Average weight loss was 15-20.9% depending on the dose — among the highest ever seen in a weight-management medication trial.

What that approval means practically: the product has been manufactured to FDA-approved standards, tested for purity and potency, studied in a large placebo-controlled trial, and is subject to FDA post-market surveillance. If Zepbound has a problem — a batch issue, an unexpected side effect — the FDA has a mechanism to learn about it and act. With a compounded product, no such centralized oversight exists.

What to ask before using any compounded tirzepatide

If you are considering compounded tirzepatide — through Puri or anywhere else — here are the questions worth asking:

• What is the API source? A reputable pharmacy will be able to tell you the API comes from an FDA-registered manufacturing facility and can provide certificates of analysis.
• Is this the base molecule or a salt form? The answer must be the base molecule. Salt forms, esters, and alternative chemistry are not the same drug and may not be safe or effective.
• What third-party testing is performed? Potency, sterility, endotoxin, and particulate testing should be performed on every lot.
• Is the pharmacy 503A or 503B? Either can be appropriate, but 503B facilities operate under stricter FDA oversight than 503A pharmacies.
• What is the pharmacy's inspection and disciplinary history? State pharmacy boards publish inspection and disciplinary records.

Puri works with pharmacies that can answer all of these questions in writing. If a telehealth platform cannot or will not answer them, that is a reason to look elsewhere.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

Compounded Tirzepatide

Compounded tirzepatide is often used by patients who cannot access brand Zepbound due to cost, supply shortages, or lack of insurance coverage. It is a legal option when prescribed by a licensed physician during an FDA-declared shortage. Patients should understand that the product has not been independently evaluated by the FDA and should use a pharmacy with documented API sourcing and quality control.

Zepbound

Zepbound is the right choice for patients who want the most clinical data behind their treatment, predictable quality from FDA oversight, and — when available — insurance coverage. It is the baseline standard against which any alternative should be weighed.